Compare APAM & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APAM | QURE |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2011 | 2013 |
| Metric | APAM | QURE |
|---|---|---|
| Price | $41.57 | $44.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $43.00 | ★ $45.00 |
| AVG Volume (30 Days) | 691.8K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 10.81% | N/A |
| EPS Growth | 10.66 | ★ 29.67 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $1,196,688,000.00 | $13,107,000.00 |
| Revenue This Year | $5.96 | $126.12 |
| Revenue Next Year | $5.05 | $200.43 |
| P/E Ratio | $21.67 | ★ N/A |
| Revenue Growth | ★ 7.63 | N/A |
| 52 Week Low | $33.96 | $8.73 |
| 52 Week High | $46.53 | $71.50 |
| Indicator | APAM | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 43.92 |
| Support Level | $40.46 | $39.50 |
| Resistance Level | $42.74 | $51.09 |
| Average True Range (ATR) | 1.00 | 2.09 |
| MACD | -0.36 | -0.66 |
| Stochastic Oscillator | 19.90 | 6.76 |
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. The company operates as one segment in the investment management business. The company generates maximum portion of its revenues from clients domiciled in countries outside the United States.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.